Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older of any sex, gender, race, or ethnicity.
• People who have signed a consent form and are willing to follow all study procedures for the full duration of the trial.
• People who have been diagnosed with a specific type of brain tumour called glioblastoma (IDH-wildtype), confirmed by laboratory tissue testing according to 2021 World Health Organization standards, regardless of a gene marker called MGMT status.
• People who have enough tumour tissue available for the required MGMT and IDH laboratory tests.
• People whose general health and ability to carry out daily activities meets a minimum level, meaning they are able to look after themselves with occasional help from others (this is measured using a standard scale called the Karnofsky Performance Status, with a score of 70% or above required).
• People whose liver, kidney, and bone marrow are functioning adequately, based on blood test results taken within the 14 days before joining the trial, including sufficient levels of blood cells, platelets, and liver-related markers.
• People who are able to become pregnant must have a negative pregnancy test and must have been using a highly effective form of contraception for at least one month before screening, and must agree to continue using it during the trial.
• People who have no other current cancer, except for certain early-stage or low-risk cancers that have been fully treated and removed, or other prior cancers from which the person has been completely free of disease for at least 3 years.

Who may not be able to join:

• People who are currently pregnant or breastfeeding, as the study drugs may be harmful to a developing baby or nursing infant.
• People who are currently receiving other treatments for their brain tumour, such as other chemotherapy or experimental drugs.
• People with a current or previous cancer diagnosis, unless it was a fully treated skin cancer (basal cell carcinoma) or carcinoma-in-situ, or unless they have been completely free of any cancer for at least 3 years.
• People who have had a second brain surgery (repeat craniotomy) to treat their tumour after already receiving radiation therapy and the chemotherapy drug temozolomide.
• People who received additional chemotherapy or experimental drugs alongside their radiation therapy and temozolomide treatment.
• People who have previously taken a drug called ruxolitinib, or who have a known allergy to any ingredient in the study drug.
• People who are currently taking the blood-thinning medication warfarin.
• People with an uncontrolled HIV infection or active tuberculosis.
• People who currently have a serious infection that requires treatment with medication.
• People with an active hepatitis B or hepatitis C infection that requires treatment, or who are considered at risk of hepatitis B reactivation based on certain blood test results (confirm with trial site).
• People with significant abnormalities on a heart tracing test (ECG), or who have serious heart or cardiovascular conditions such as uncontrolled irregular heartbeat, moderate-to-severe heart failure, uncontrolled high blood pressure, heart valve disease, inflammation around the heart, a heart attack, or a blood clot event such as a pulmonary embolism or deep vein thrombosis within the past 6 months.
• People with any other serious medical or psychiatric condition that, in the opinion of the trial doctor, is likely to interfere with participation or compliance with the study.

Important: Always verify eligibility with the trial site directly before applying.